Besides, dysregulated signaling pathways like Wnt/β-catenin, NF-κB, and PI3K/AKT/mTOR contribute to tumor progression and resistance to treatment [7–9], highlighting the urgent need for more effective and targeted therapies. This evidence concerns the gene AKT1 and neoplasm.